de Jong, L. A., van der Velden, A. W. G., van Hulst, M., & Postma, M. J. (2020). Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism. BMJ Open.
Dyfyniad Arddull Chicagode Jong, Lisa A., Annette W G. van der Velden, Marinus van Hulst, and Maarten J. Postma. "Cost-effectiveness Analysis and Budget Impact of Rivaroxaban Compared With Dalteparin in Patients With Cancer At Risk of Recurrent Venous Thromboembolism." BMJ Open 2020.
Dyfyniad MLAde Jong, Lisa A., Annette W G. van der Velden, Marinus van Hulst, and Maarten J. Postma. "Cost-effectiveness Analysis and Budget Impact of Rivaroxaban Compared With Dalteparin in Patients With Cancer At Risk of Recurrent Venous Thromboembolism." BMJ Open 2020.